Nordicus Partners Corp (NORD) stock: key figures, P/E, revenue and dividend

Industrials · United States · ISIN USG6583A1028

Price
5.09 USD
Market cap
98.97 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-6.23 %
Return on assets (ROA)
-5.30 %

Nordicus Partners Corp financials

Fiscal year20252026
Revenue5,000.00 USD–
Operating income-2.92 m USD-4.37 m USD
EBIT-2.92 m USD-4.05 m USD
Net income-2.90 m USD-4.00 m USD
Diluted EPS – continuing operations-0.32 USD-0.22 USD

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Nordicus Partners Corp

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.